Physician profile
Mary Sheehan
NPI 1407869829
$15,604.17
in general payments reported to CMS, 2019-2025
20 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,722 · 2021: $507 · 2022: $514 · 2023: $247 · 2024: $235 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $11,393.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $753.29 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $519.79 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $486.61 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $430.70 | 2019-2020 | |
| Abbvie INC. | $342.90 | 2019-2023 | Vraylar |
| Eisai INC. | $271.13 | 2020-2021 | |
| Alkermes, INC. | $259.33 | 2019-2024 | Vivitrol |
| Jazz Pharmaceuticals INC. | $243.74 | 2021-2022 | |
| Allergan, INC. | $167.79 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.58 | 2022-2023 | |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Livanova USA, INC. | $121.44 | 2021 | |
| Braeburn INC. | $91.09 | 2024 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $89.99 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $54.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.62 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.22 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.17 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.